IndyCar Driver Makes Pit Stop at UC Cancer Institute
Just days before the 98th running of the Indianapolis 500, IndyCar driver Pippa Mann visited with researchers and clinicians at University of Cincinnati Cancer Institute.
Mann, who drives a pink Susan G. Komen Verizon IndyCar series car, partnered with the Susan G. Komen Foundation for a visit to the lab of Xiaoting Zhang, PhD, associate professor in the UC Department of Cancer Biology. The visit, held Tuesday, May 20, was part of the Indianapolis 500's annual media day, when each of the 33 drivers travel across the country to make appearances and meet with journalists.
Zhang is a Komen-supported researcher with the Cincinnati Cancer Center and UC Cancer Institute. He uses nanoparticles to study why certain cancers become resistant to the drug tamoxifen.
Following a tour of Zhang's lab in the Vontz Center for Molecular Studies, Mann visited clinicans at the UC Health Barrett Center. Elyse Lower, MD, director of the UC Cancer Institute's Comprehensive Breast Cancer Center and professor in the hematology oncology division at UC, led Mann on a tour through areas newly renovated through the Rooms that Rock for Chemo project.
Mann took to social media during her trip to Cincinnati and from her Twitter account ( @PippaMann), posted to her nearly 18,000 followers: "Amazing tour with @SusanGKomen co-sponsored researcher Dr. Zhang at @uofcincy. Massively important work. #breastcancer #500MediaDay."
Xiaoting Zhang, PhD (left), with IndyCar driver Pippa Mann.
Xiaoting Zhang, PhD (left), with IndyCar driver Pippa Mann and Elyse Lower, MD (right).
Tags
Related Stories
Can new research improve the safety of AI therapy for teens?
December 5, 2025
The University of Cincinnati's Stephen Rush joined WVXU's Cincinnati Edition for a discussion on the growing trend of young people turning to artificial intelligence for mental health support and therapy.
Student-designed AI platform aims to match patients to specific cancer support groups
December 5, 2025
The University of Cincinnati is launching a clinical trial testing a student-designed, machine-learning powered platform to match patients with cancer to support groups specifically tailored to their needs and concerns.
What would expanded access to GLP-1s mean for the obesity rate?
December 4, 2025
The World Health Organization recently issued its first guidance on GLP-1 medications for adults with obesity — recommending long-term, continuous use when clinically appropriate. Malti Vij, MD, University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine, appeared on Cincinnati Edition on 91.7 WVXU News to discuss GLP-1s and what expanded insurance coverage of the medications might mean for Americans.